Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines.
Cross-linkage of the Fas antigen induces programmed cell death in many normal and malignant lymphoid cells by a process known as apoptosis. In this study, we examined the sensitivity of myeloma cell lines and patient plasma cells to a cytolytic anti-Fas monoclonal antibody (MoAb). Eight of 10 myeloma cell lines were induced to undergo programmed cell death by anti-Fas MoAb as determined by DNA fragmentation and morphologic changes. Of the two myeloma cell lines that were resistant to anti-Fas treatment, one did not express the Fas antigen. Only the U266 cell line expressed Fas, but was not killed by the anti0Fas MoAb. To extend these studies, we have examined the expression and function of Fas in freshly isolated CD38hiCD45neg-int plasma cells from patients with multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), and primary amyloidosis (AL). By three-color flow cytometry, we found Fas expression in CD38hiCD45neg-int plasma cells from all patient groups to be variable, as Fas was expressed in 15 of 28 MM, 3 of 6 MGUS, and 2 of 7 AL patients. In morphologic studies of apoptosis, Fas-positive myeloma cells in patient bone marrow mononuclear cell (MNC) cultures appeared to be resistant to anti-Fas-mediated apoptosis. By contrast, purified myeloma cells from the same patient were sensitive to anti-Fas treatment, suggesting the presence of a protective factor(s) in unseparated MNC cultures that may inhibit Fas-induced apoptosis of plasma cells. Of interest, serum from normal individuals and myeloma patients also protected myeloma cell lines from undergoing Fas-mediated apoptosis. These studies show that Fas expression in myeloma cell lines and CD38hiCD45neg-int patient plasma cells is variable and may reflect a variance in the maturation status of the various plasma cell populations. Moreover, Fas-mediated killing of patient cells and myeloma cell lines was also variable, which may be influenced, in part, by the presence of a soluble protective factor.
Westendorf
J J
JJ
Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.
Lammert
J M
JM
Jelinek
D F
DF
D000686:Amyloidosis / Q000378:metabolism* / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000954:Antigens, Surface / Q000096:biosynthesis* / Q000276:immunology; D017209:Apoptosis / Q000187:drug effects; D001853:Bone Marrow / Q000473:pathology; D005434:Flow Cytometry; D006801:Humans; D009101:Multiple Myeloma / Q000378:metabolism* / Q000473:pathology; D010265:Paraproteinemias / Q000378:metabolism* / Q000473:pathology; D014407:Tumor Cells, Cultured; D019014:fas Receptor
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D019014:fas Receptor